Histone deacetylase 3 as a novel therapeutic target in multiple myeloma-Reference-Cited by-同舟云学术

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Published:2013-08-05 Issue:3 Volume:28 Page:680-689
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Minami J,Suzuki R,Mazitschek R,Gorgun G,Ghosh B,Cirstea D,Hu Y,Mimura N,Ohguchi H,Cottini F,Jakubikova J,Munshi N C,Haggarty S J,Richardson P G,Hideshima T,Anderson K C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013231.pdf

Reference33 articles.

1. Quintas-Cardama A, Santos FP, Garcia-Manero G . Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226–235.

2. Deangelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27: 1628–1636.

3. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009; 23: 1507–1514.

4. Lane AA, Chabner BA . Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459–5468.

5. Dimopoulos M, Jagannath S, Yoon S-S, Siegel D, Lonial S, Hajek R et al. Vantage 088. Vorinostst in combination with bortezomib in patients with relapsed refractory multiple myeloma: results of a global randomized phase 3 trial. Blood 2011; 118: 368–369.

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

2. Donkey milk inhibits tumor growth by inducing apoptosis, pyroptosis and modulation of Th1/Th2 responses in a 4T1 murine breast cancer model;Journal of Functional Foods;2024-07

3. Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia;Annals of Hematology;2024-06-07

4. Exploring different classification-dependent QSAR modelling strategies for HDAC3 inhibitors in search of meaningful structural contributors;SAR and QSAR in Environmental Research;2024-05-03

5. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial;Cancers;2024-04-09